Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 3, 24

Actions of N-arachidonyl-glycine in a Rat Inflammatory Pain Model

Affiliations

Actions of N-arachidonyl-glycine in a Rat Inflammatory Pain Model

Rebecca Succar et al. Mol Pain.

Abstract

Background: While cannabinoid receptor agonists have analgesic activity in inflammatory pain states they produce a range of side effects. Recently, it has been demonstrated that the arachidonic acid-amino acid conjugate, N-arachidonyl-glycine (NA-glycine) is effective in acute pain models.

Results: In the present study we examined the effect of NA-glycine in a rat model of inflammatory pain. Intrathecal administration of NA-glycine (70 - 700 nmol) and the pan-cannabinoid receptor agonist HU-210 (10 nmol) reduced the mechanical allodynia and thermal hyperalgesia induced by intraplantar injection of Freund's complete adjuvant (FCA). The actions of HU-210, but not NA-glycine were reduced by the cannabinoid CB1 receptor antagonist AM251. The cannabinoid CB2 receptor antagonist SR144528 also had no effect on the actions of NA-glycine. In contrast, N-arachidonyl-GABA (NA-GABA, 700 nmol) and N-arachidonyl-alanine (NA-alanine, 700 nmol) had no effect on allodynia and hyperalgesia. HU-210, but not NA-glycine produced a reduction in rotarod latency.

Conclusion: These findings suggest that NA-glycine may provide a novel non-cannabinoid receptor mediated approach to alleviate inflammatory pain.

Figures

Figure 1
Figure 1
NA-glycine reduces mechanical allodynia. (a) Time plots of the effect of NA-glycine (NAGly,700 nmol, filled circles), HU-210 (10 nmol, filled squares), or vehicle (open circles) on mechanical paw withdrawal threshold (Mech PWT). Animals received an intrathecal injection of NA-glycine, HU-210 or a matched vehicle at time 0 h, 24 h after intraplantar injection of FCA. Data is also shown prior to FCA injection (Pre-FCA). (b) Bar charts depicting the effect of intrathecal injection of combinations of NA-glycine (NAGly 70 – 700 nmol), HU-210 (10 nmol), AM251 (30 nmol) and vehicle on mean mechanical paw withdrawal threshold, measured as the area-under-the-curve (AUC). * denotes P < 0.05, ** P < 0.01 and # P < 0.0001 compared to time 0 post-FCA in (a) and to vehicle in (b).
Figure 2
Figure 2
NA-glycine reduces thermal hyperalgesia. (a) Time plots of the effect of NA-glycine (NAGly,700 nmol, filled circles), HU-210 (10 nmol, filled squares), or vehicle (open circles) on thermal paw withdrawal latency (PWL). Animals received an intrathecal injection of NA-glycine, HU-210 or a matched vehicle at time 0 h, 24 h after intraplantar injection of FCA. Data is also shown prior to FCA injection (Pre-FCA). (b) Bar charts depicting the effect of intrathecal injection of combinations of NA-glycine (NAGly 70 – 700 nmol), HU-210 (10 nmol), AM251 (30 nmol) and vehicle on mean thermal paw withdrawal latency, measured as the area-under-the-curve (AUC). * denotes P < 0.05, ** P < 0.01 and # P < 0.0001 compared to time 0 post-FCA in (a) and vehicle in (b).
Figure 3
Figure 3
NA-glycine does not affect motor function. Time plots of the effect of NA-glycine (NAGly,700 nmol, filled circles), HU-210 (10 nmol, filled squares), or vehicle (open circles) on rotarod latency. Animals received an intrathecal injection of NA-glycine, HU-210 or a matched vehicle at time 0 h,24 h after intraplantar injection of FCA. Rotarod latency is shown as the difference to the latency at the time zero point, with negative values indicating a decrease in latency. * denotes P < 0.05, ** P < 0.01 and # P < 0.0001 compared to time 0.

Similar articles

See all similar articles

Cited by 23 PubMed Central articles

See all "Cited by" articles

References

    1. Pertwee RG. Pharmacological actions of cannabinoids. In: Pertwee RG, editor. Handbook of Experimental Pharmacology: Cannabinoids. Vol. 168. Berlin , Springer; 2005. pp. 1–51. - PubMed
    1. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain. 2002;96:253–260. doi: 10.1016/S0304-3959(01)00454-7. - DOI - PubMed
    1. Smith FL, Fujimori K, Lowe J, Welch SP. Characterization of D9-tetrahydrocannabinol and Anandamide Antinociception in Nonarthritic and Arthritic Rats. Pharmacol Biochem Behav. 1998;60:183–191. doi: 10.1016/S0091-3057(97)00583-2. - DOI - PubMed
    1. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, Simone DA. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain. 2003;103:175–186. doi: 10.1016/S0304-3959(02)00450-5. - DOI - PubMed
    1. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96:14228–14233. doi: 10.1073/pnas.96.25.14228. - DOI - PMC - PubMed

Publication types

LinkOut - more resources

Feedback